Priyanka Aswal*
Artificial intelligence, predictive, and other superior technologies are speedily being integrated into pharmaceutical companies across the world. The interest in AI-centered solutions for early at the time of drug invention is steadily picking momentum among biopharma in which there is a projected market volume of approximately $10B by 2024 across all AI-driven medical diagnostics, medical imaging, drug discovery, genomics, and personal AI assistants. In the past few years, there has been a tremendous wave of modern R and D partnerships between potential biopharma stakeholders and AI-based corporates, especially the startups. Since the majorities of AI-centered companies maximize various techniques of and use interdisciplinary sources of data in modeling their work, the paper looks into different ways AI can be used in the pharmaceutical industry.
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi